Researchers Identify Metabolomics as a Potential Tool to Improve Diagnostic and Prognostic Information on AMD July 9, 2019 A recent meta-analysis, led by Deeba Husain, MD, suggests that AMD patients present distinct plasma metabolomic profiles, which vary with disease severity. After analyzing blood samples of their 491 patients from two cohorts–one in Boston and one in Coimbra, Portugal–they found that metabolites differed significantly between AMD patients as compared to controls, and with various stages of the disease.... Read more about Researchers Identify Metabolomics as a Potential Tool to Improve Diagnostic and Prognostic Information on AMD
Gene Therapy Platform Developed by Neena Haider, PhD, Granted FDA Orphan Drug Designation February 27, 2019OCU400, a novel gene therapy platform developed by Neena Haider, PhD, Harvard Medical School Associate Professor of Ophthalmology and Associate Scientist at the Schepens Eye Research Institute of Mass. Eye and Ear, and licensed to biopharmaceutical company Ocugen, Inc., has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA).... Read more about Gene Therapy Platform Developed by Neena Haider, PhD, Granted FDA Orphan Drug Designation
Neuroglial Remodeling After Injury May Contribute to Retinal Degeneration November 19, 2018 A study led by Eleftherios Paschalis, PhD, describes a mechanism by which patients with acute ocular injuries become susceptible to progressive neurodegeneration long after the injury has taken place.... Read more about Neuroglial Remodeling After Injury May Contribute to Retinal Degeneration
A study led by